SIRT1 and breast carcinoma: In contrast, in lung cancer cell lines, NAMPT inhibition activated EMT and increased cellular invasiveness also through decreased SIRT1 (85), and in breast cancer models, NAMPT inhibition enhanced metastatic behavior (139), suggesting the impact of NAMPT inhibition on EMT may be cell-type specific.